Our Scientific Advisory Board 2018
Our SAB for 2018 comprised of five leading scientists experienced in neuroblastoma research. The Chair of our SAB is paediatric oncology clinician.
Dr Guy Makin CHAIRMAN
Senior Lecturer in Paediatric Oncology, Honorary Consultant Paediatric Oncologist at Royal Manchester Children’s Hospital.
Guy graduated from Oxford in 1991, and trained in Oxford, Birmingham, Bristol, Sheffield and Manchester. He was appointed as Senior Lecturer and Honorary Consultant in 2001. He has been a member of the NCRI Children’s Cancer and Leukaemia Clinical (CCL) Studies Group (since 2013), CCL neuroblastoma group (since 2010) and New Agents Group (since 2010).
Guy is also National Lead for the Paediatric Experimental Cancer Medicine Centre (ECMC) network. He is the UK Chief Investigator for the SIOPEN phase II VERITAS study of two intensification strategies in metastatic neuroblastoma. Since 2013 he has been the Director of the MRes in Oncology for The University of Manchester. Guy has also been Training Program Director for Paediatrics ST4-8 for Greater Manchester and Lancashire since 2008.
Prof Bengt Hallberg (Gothenburg)
Bengt Hallberg is currently Professor at Department of Medical Biochemistry and Cell biology at the University of Gothenburg ad Principal Investigator at the Bengt Hallberg Lab.
Prof Anna Philpott (Cambridge)
Anna Philpott graduated from the University of Cambridge with a BA degree in Natural Sciences in 1988 and a PhD in Molecular Cell Biology in 1991. She held post-doctoral fellowships at Massachusetts General Hospital Cancer Centre in 1992, moving to the Department of Cell Biology at Harvard Medical School in 1993.
She returned to the University of Cambridge in 1998 to a Lectureship in the Department of Oncology, where she is currently Professor of Cancer and Developmental Biology.
Dr. Gudrun Schleiermacher is a paediatric oncologist and head of a research team at Institut Curie, Paris. She is strongly involved in national and international clinical research, in particular in the field of neuroblastoma.
Dr Gudrun Schleiermacher (Institut Curie)
Frank Westerman is currently Head of Department at the German Cancer Research Centre (DFKZ) for Neuroblastoma Genomics and German Cancer Consortium (DKTK).
Dr Frank Westermann (Heidelberg)
Peter Ambros is Professor Emeritus at Children's Cancer Research Institute in Vienna, Austria. His research team aim to establish, validate and apply new diagnostic and therapeutic tools to facilitate precision medicine to treat children with malignant tumours.